(s, 1H), 7.03 (br, 1H); 13C NMR (CDCl3 333 K) d 29.8, 31.5,
47.1, 56.7, 75.2, 75.9, 94.9, 116.6, 140.9, 153.7, 154.4; HRMS
C14H20Cl6N2O4 [M + Na]+ calcd 512.9452, found 512.9803
1-(4,4-Dimethyl-2-methylene-penten-1-yl)-1,2-hydrazinedi-
carboxylic acid bis(2,2,2-trichloroethyl) ester 3e and 1-(1-tert-
butyl-2-methyl-allyl)-1,2-hydrazine dicarboxylic acid bis(2,2,2-
trichloroethyl) ester 3f. Colorless solid. 1H NMR (CDCl3
333 K) d 0.94 and 1.02 (s, 3f and s, 3e, 9H), 1.88 and 1.93 (2s, 3e
and 3f, 3H), 4.20 and 4.52 (br, 3e and br s, 3f, 2H), 4.77 and 4.79
(2s, 3e and 3f, 4H), 4.96 (s, 3e, 1H), 5.03 (s, 3e, 1H), 5.12 (br, 3f,
1H), 5.17 (br, 3f 1H), 6.60 (br, 3e, 1H), 6.87 (br, 3f, 1H); HRMS
C14H20Cl6N2O4 [M + Na]+ calcd 512.9452, found 512.9451.
(E)-1-(2-Hexen-4-yl)-1,2-hydrazinedicarboxylic acid bis(2,2,2-
trichloroethyl) ester 3g. Colorless oil. 1H NMR (CDCl3 333 K)
d 0.93 (t, J = 7.6 Hz, 3H), 1.53–1.62 (m, 1H), 1.67 (d, J = 6 Hz,
3H), 1.70–1.78 (m, 1H), 4.46–4.52 (m, 1H), 4.76–4.79 (m, 4H),
5.44 (dd, J = 15.2, 7.2 Hz, 1H), 5.70 (dq, J = 15.6, 6.8 Hz,
1H), 6.62 (br, 1H); 13C NMR (CDCl3, 333 K) d 10.8, 17.7, 24.9,
63.1, 75.3, 75.8, 94.9, 95.1, 128.0, 129.7, 154.1, 154.6; HRMS
C12H16Cl6N2O4 [M + Na]+ calcd 484.9139, found 484.9102.
(E)-1-(2-Penten-1-yl)-1,2-hydrazinedicarboxylic acid bis(2,2,2-
trichloroethyl) ester 3h. Colorless oil. 1H NMR (CDCl3 333 K)
d (t, J = 7.6 Hz, 3H), 2.04 (quintet, J = 7.6 Hz, 2H), 4.13
(d, J = 6 Hz, 2H), 4.74 (s, 4H), 5.44–5.51 (m, 1H), 5.69–5.76
(m, 1H), 7.03 (br, 1H); 13C NMR (CDCl3, 333 K) d 13.2, 25.2,
52.7, 75.2, 75.8, 94.9, 95.0, 121.8, 138.4, 153.9, 154.0; HRMS
C11H14Cl6N2O4 [M + Na]+ calcd 470.8982, found 470.8979.
J = 6.8 Hz, 3H), 1.50–1.64 (m, 4H), 1.88–2.09 (m, 4H), 4.02 (t,
J = 8.4 Hz, 2H), 4.43 (t, J = 8.8 Hz 2H), 4.69–4.79 (m, 3H),
5.64–5.66 (m, 1H), 9.14 (s, 1H); 13C NMR (CDCl3, 333 K) d
15.1, 22.1, 22.6, 25.1, 26.7, 42.4, 58.9, 62.9, 75.6, 95.1, 124.7,
135.5, 151.5, 153.7, 155.2; HRMS C15H20Cl3N3O5 [M + Na]+
calcd 450.0366, found 450.0365.
Nꢀ -(1-Ethyl-but-2-enyl)-Nꢀ -(2-oxo-oxazolidine-3-carbonyl)-
hydrazinecarboxylic acid 2,2,2-trichloro-ethyl ester 6c.
Colorless oil. The enantiomers were separated by HPLC
using a Chiralpak AD chiral stationary phase in hexane–i-
PrOH 80 : 20 (smajor = 6.07 min, sminor = 6.90 min). [a]Drt
=
−2.1 (c = 1.0, CHCl3, 7% ee); 1H NMR (CDCl3 333 K) d 0.94
(t, J = 6.4 Hz, 3H), 1.47–1.77 (m, 5H), 4.11–4.84 (m, 7H),
5.43–5.49 (m, 1H), 5.69–5.78 (m, 1H), 7.76 (br s, 1H); HRMS
C13H18Cl3N3O5 [M + Na]+ calcd 424.0210, found 424.0221.
N-(1-Ethyl-but-2-enyl)-Nꢀ -(2-oxo-oxazolidine-3-carbonyl)-
hydrazinecarboxylic acid 2,2,2-trichloro-ethyl ester 7c.
Colorless oil. The enantiomers were separated by HPLC
using a Chiralpak AD chiral stationary phase in hexane–i-
PrOH 80 : 20 (sminor = 7.93 min, smajor = 9.20 min). [a]rDt = +2.1
1
(c = 1.0, CHCl3, 33% ee); H NMR (CDCl3 333 K) d 0.96 (t,
J = 7.6 Hz, 3H), 1.53–1.77 (m, 5H), 4.04 (t, J = 8.4 Hz, 2H),
4.42–4.53 (m, 3H), 4.74 (br, 2H), 5.44 (dd, J = 15.6, 7.6 Hz,
1H), 5.67–5.73 (m, 1H), 9.22 (s, 1H); 13C NMR (CDCl3, 333 K)
d 10.7, 17.6, 25.0, 42.5, 62.1, 63.0, 75.7, 95.2, 128.1, 129.6,
151.8, 153.7, 155.3; HRMS C13H18Cl3N3O5 [M + Na]+ calcd
424.0210, found 424.0209.
General procedure for catalytic enantioselective aza-ene
reactions
General procedure for catalytic enantioselective
hetero-Diels–Alder reactions
In an oven dried Schlenk tube equipped with a magnetic
stirrer bar, Cu(OTf)2 (36.2 mg, 0.1 mmol) and (R)-(+)-2,2-
isopropylidene-bis(4-phenyl-2-oxazoline) (36.8 mg, 0.11 mmol)
were added. The mixture was stirred under a vacuum
for 2 h and filled with N2. Dry CH2Cl2 (1 mL) was added
and the solution stirred for 1 h. 160 mg (0.5 mmol) of 2,2,2-
trichloroethyl{[(2-oxo-1,3-oxazolidin-3-yl)carbonyl]diazenyl}-
formate 2c was added, followed by the addition of the alkene
(1 mmol) and stirred at rt. After the time indicated in the table
the product was isolated by FC (CH2Cl2 : EtOAc 4 : 1).
In a oven dried Schlenk tube equipped with a magnetic
stirrer bar, Cu(OTf)2 (18,1 mg, 0.05 mmol) and (R)-(+)-2,2-
isopropilidene-bis(4phenyl-2-oxazoline) (18.4 mg, 0.055 mmol)
were added. The mixture was stirred under a vacuum for
2 h and filled with N2. Dry CH2Cl2 (1 mL) was added and
the solution stirred for 1 h. 160 mg (0.5 mmol) of 2,2,2-
trichloroethyl{[(2-oxo-1,3-oxazolidin-3-yl)carbonyl]diazenyl}-
formate 2c was added, followed by the addition of
cyclopentadiene 9 (33 mg, 0.5 mmol) and stirring at rt.
After the time indicated in the table the product was isolated by
FC (CH2Cl2 : EtOAc 4 : 1).
Nꢀ-Cyclopent-2-enyl-Nꢀ-(2-oxo-oxazolidine-3-carbonyl)-hydra-
zinecarboxylic acid 2,2,2-trichloro-ethyl ester 6a. Colorless
solid. Mp = 88–90 ◦C. The enantiomers were separated
by HPLC using a Chiralpak AD chiral stationary phase in
hexane–i-PrOH 80 : 20 (smajor = 10.13 min, sminor = 9.04 min).
[a]rDt = −16.3 (c = 1.0, CHCl3, 40% ee); 1H NMR (CDCl3 333 K)
d 2.17–2.42 (m, 4H), 4.01–4.89 (m, 6H), 5.39 (br s, 1H), 5.67
(br s, 1H), 6.01 (br s, 1H), 7.74 (br s, 1H); 13C NMR (CDCl3
333 K) d 27.1, 31.4, 44.1, 63.1, 65.6, 74.9, 94.0, 127.8, 136.6,
150.0, 153.5, 153.9; HRMS C12H14Cl3N3O5 [M + Na]+ calcd
407.9879, found 407.9907.
3-(2-Oxo-oxazolidine-3-carbonyl)-2,3-diaza-bicyclo-[2.2.1]-
hept-5-ene-2-carboxylic acid 2,2,2-trichloro-ethyl ester 8a.
Colorless solid. Mp = 159–160 ◦C. The enantiomers were
separated by HPLC using a Daicel Chiralcel OD–R chiral
stationary phase in MeOH–MeCN 90 : 10, 22% ee (smajor
=
8.86 min, sminor = 11.11 min). [a]rDt = −10.9 (c = 1.0, CHCl3);
1H NMR (CDCl3 333 K) d 1.82 (d, J = 8.8 Hz, 1H), 1.97 (d,
J = 8.8 Hz, 1H), 3.92–3.98 (m, 1H), 4.12 (q, J = 9.2 Hz, 1H),
4.35–4.46 (m, 2H), 4.68 (d, J = 12 Hz, 1H), 4.79 (d, J = 12 Hz,
1H), 5.20 (br, 2H), 6.57–6.62 (m, 2H); 13C NMR (CDCl3, 333 K)
d 44.1, 47.5, 62.4, 64.9, 69.1, 75.5, 95.0, 135.7, 137.1, 152.5,
153.5, 155.1; HRMS C12H12Cl3N3O5 [M + K]+ calcd 405.9530,
found 405.9594.
N-Cyclopent-2-enyl-N’-(2-oxo-oxazolidine-3-carbonyl)-hydra-
zinecarboxylic acid 2,2,2-trichloro-ethyl ester 7a. Colorless
1
solid. H NMR (CDCl3 333 K) d 1.91 (br s, 1H), 2.22–2.31
(m, 2H), 2.39–2.49 (m, 1H), 4.02 (t, J = 8.4 Hz, 2H), 4.44 (t,
J = 8.6 Hz, 2H), 4.74 (s, 2H), 5.37–5.40 (m, 1H), 5.68–5.70 (m,
1H), 5.99–6.02 (m, 1H), 9.21 (s, 1H); 13C NMR (CDCl3, 333 K)
d 27.5, 31.4, 42.5, 63.0, 65.7, 75.8, 95.2, 128.1, 136.5, 151.9,
155.2; HRMS C12H14Cl3N3O5 [M + Na]+ calcd 407.9879, found
407.9886.
3-(2-Oxo-oxazolidine-3-carbonyl)-2,3-diaza-bicyclo-[2.2.1]-
hept-5-ene-2-carboxylic acid benzyl ester 8b. Colorless foam.
The enantiomers were separated by HPLC using a Daicel
Chiralcel OD–R chiral stationary phase in MeOH–MeCN
90 : 10, 20% ee (sminor = 15.94 min, smajor = 17.51 min). [a]Drt
=
−6.9 (c = 1.0, CHCl3); 1H NMR (CDCl3 333 K) d 1.70 (d, J =
8.8 Hz, 1H), 1.85 (d, J = 8.8 Hz, 1H), 3.82–3.88 (m, 1H), 4.05
(q, J = 9.2 Hz, 1H), 4.24–4.36 (m, 2H), 5.06–5.21 (m, 4H),
6.43–6.47 (m, 2H), 7.23 (br, 5H); 13C NMR (CDCl3, 333 K)
d 43.9, 47.3, 62.3, 64.5, 67.7, 68.7, 127.5, 127.9, 128.3, 135.3,
136.9, 152.6, 153.4, 157.1; HRMS C17H17N3O5 [M + K]+ calcd
366.0879, found 366.0879.
N-(1-Cyclohex-1-enyl-ethyl)-N’-(2-oxo-oxazolidine-3-carbonyl)-
hydrazinecarboxylic acid 2,2,2-trichloro-ethyl ester 7b.
Colorless oil. The enantiomers were separated by HPLC
using a Chiralpak AD chiral stationary phase in hexane–i-
PrOH 80 : 20 (sminor = 8.09 min, smajor = 9.59 min). [a]rDt = −19.2
1
(c = 1.0, CHCl3, 60% ee); H NMR (CDCl3 333 K) d 1.30 (d,
2 3 4 8
O r g . B i o m o l . C h e m . , 2 0 0 5 , 3 , 2 3 4 4 – 2 3 4 9